Dow Jones component Johnson & Johnson (JNJ) saw its stock move 0.13% to $102.45, representing a per-share move of $0.13, on volume of 5.98 million shares for Wednesday.
Johnson & Johnson currently has a total float of 2.77 billion shares and moves 11.13 million a day, on average. The stock opened at $102.75 on February 17 and traded between a low of $102.23 and a high of $103.24. The stock now has a 50-day SMA of $101.33 and 200-day SMA of $98.34, and it has a high of $105.49 and low of $81.79 over the last year. Its P/E ratio is 18.6 and its P/B ratio is 3.96.
Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of products in the health care field within its Consumer, Pharmaceutical and Medical Devices, and Diagnostics business segments.
Based out of New Brunswick, NJ, Johnson & Johnson has 126,500 employees and is helmed by CEO Alex Gorsky.
For a deeper dive into the fundamentals of Johnson & Johnson, check out equities.com’s E.V.A. report for JNJ.
GET TO KNOW THE DOW
The Dow Jones Industrial Average is the oldest and most-often cited stock market index for the American equities market. While it’s arguably outdated and inefficient, it remains the most visible representation of the stock market to the outside world. Consisting of 30 companies selected by the editorial board of the Wall Street Journal, it’s meant to give an overview of stock performances by looking at a slice of those mega- and large-cap companies deemed to best represent the broad economy.
The history of the index dates all the way back to 1896 when it was first created by Charles Dow, the legendary founding editor of the Wall Street Journal and founder of Dow Jones & Company, and Edward Jones, a statistician. The price-weighted, scaled index has since become a standard part of most major daily news recaps and has seen dozens of different companies pass through its ranks, with only General Electric (GE) remaining on the index since its inception.
For more news on the financial markets, go to Equities.com. Also, learn more about our independent proprietary equity research reports and our robust do-it-yourself Stock Valuation Analysis reports in our Research section.
All data provided by QuoteMedia and was accurate as of 4:30PM ET.
DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer